



(51) International Patent Classification:

C07K 16/24 (2006.01) A61P 37/08 (2006.01)
C07K 16/18 (2006.01) A61K 39/395 (2006.01)

(21) International Application Number:

PCT/EP2020/087046

(22) International Filing Date:

18 December 2020 (18.12.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

1919061.0 20 December 2019 (20.12.2019) GB

(71) Applicant: UCB BIOPHARMA SRL [BE/BE]; Allée de la Recherche, 60, 1070 Brussels (BE).

(72) Inventors: **KHAN, Adnan Rahman**; c/o IPD, UCB CELLTECH, 208 Bath Road, Slough Berkshire SL1 3WE (GB). **HEYWOOD, Sam Philip**; c/o IPD, UCB CELLTECH, 208 Bath Road, Slough Berkshire SL1 3WE (GB). **HUMPHREYS, David Paul**; c/o IPD, UCB CELLTECH, 208 Bath Road, Slough Berkshire SL1 3WE (GB). **LIGHTWOOD, Daniel John**; c/o IPD, UCB CELLTECH, 208 Bath Road, Slough Berkshire SL1 3WE (GB). **DAVE, Emma**; c/o IPD, UCB CELLTECH, 208 Bath Road, Slough

Berkshire SL1 3WE (GB). **BARRY, Emily Mary Cairistine**; c/o IPD, UCB CELLTECH, 208 Bath Road, Slough Berkshire SL1 3WE (GB). **STANYON, Sarah Jayne**; c/o IPD, UCB CELLTECH, 208 Bath Road, Slough Berkshire SL1 3WE (GB).


(74) Agent: UCB INTELLECTUAL PROPERTY; c/o UCB CELLTECH, 208 Bath Road, Slough Berkshire SL1 3WE (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

(54) Title: MULTI-SPECIFIC ANTIBODY WITH BINDING SPECIFICITY FOR HUMAN IL-13 AND IL-17

Figure 6. Simultaneous neutralisation of IL-13, IL-17A and IL-17F by IL-13/IL-17AF multi-specific antibody



(57) Abstract: The present invention relates to a multi-specific antibody having specificity for human IL-13, human IL-17A and/or human IL-17F. The invention further relates to methods for producing the multi-specific antibody and to its therapeutic use for the treatment of atopic dermatitis and other diseases.

[Continued on next page]

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*